A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
The discovery of immune checkpoints and the development of immune checkpoint inhibitors (ICI) have achieved a durable response in advanced-stage cancer patients. However, there is still a high proportion of patients who do not benefit from ICI therapy due to a lack of response when first treated (pr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2308097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850063019161157632 |
|---|---|
| author | Ginette S. Santiago-Sánchez Kellsye P. Fabian James W. Hodge |
| author_facet | Ginette S. Santiago-Sánchez Kellsye P. Fabian James W. Hodge |
| author_sort | Ginette S. Santiago-Sánchez |
| collection | DOAJ |
| description | The discovery of immune checkpoints and the development of immune checkpoint inhibitors (ICI) have achieved a durable response in advanced-stage cancer patients. However, there is still a high proportion of patients who do not benefit from ICI therapy due to a lack of response when first treated (primary resistance) or detection of disease progression months after objective response is observed (acquired resistance). Here, we review the current FDA-approved ICI for the treatment of certain solid malignancies, evaluate the contrasting responses to checkpoint blockade in different cancer types, explore the known mechanisms associated with checkpoint blockade resistance (CBR), and assess current strategies in the field that seek to overcome these mechanisms. In order to improve current therapies and develop new ones, the immunotherapy field still has an unmet need in identifying other molecules that act as immune checkpoints, and uncovering other mechanisms that promote CBR. |
| format | Article |
| id | doaj-art-b071a3a9e19246f28522f4937fb9cd67 |
| institution | DOAJ |
| issn | 1538-4047 1555-8576 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cancer Biology & Therapy |
| spelling | doaj-art-b071a3a9e19246f28522f4937fb9cd672025-08-20T02:49:46ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762024-12-0125110.1080/15384047.2024.2308097A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistanceGinette S. Santiago-Sánchez0Kellsye P. Fabian1James W. Hodge2Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAThe discovery of immune checkpoints and the development of immune checkpoint inhibitors (ICI) have achieved a durable response in advanced-stage cancer patients. However, there is still a high proportion of patients who do not benefit from ICI therapy due to a lack of response when first treated (primary resistance) or detection of disease progression months after objective response is observed (acquired resistance). Here, we review the current FDA-approved ICI for the treatment of certain solid malignancies, evaluate the contrasting responses to checkpoint blockade in different cancer types, explore the known mechanisms associated with checkpoint blockade resistance (CBR), and assess current strategies in the field that seek to overcome these mechanisms. In order to improve current therapies and develop new ones, the immunotherapy field still has an unmet need in identifying other molecules that act as immune checkpoints, and uncovering other mechanisms that promote CBR.https://www.tandfonline.com/doi/10.1080/15384047.2024.2308097Immune checkpoint inhibitors (ICI)immune checkpoint blockadecheckpoint blockade resistanceimmunotherapy resistancecheckpoint blockade resistance mechanisms |
| spellingShingle | Ginette S. Santiago-Sánchez Kellsye P. Fabian James W. Hodge A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance Cancer Biology & Therapy Immune checkpoint inhibitors (ICI) immune checkpoint blockade checkpoint blockade resistance immunotherapy resistance checkpoint blockade resistance mechanisms |
| title | A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance |
| title_full | A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance |
| title_fullStr | A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance |
| title_full_unstemmed | A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance |
| title_short | A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance |
| title_sort | landscape of checkpoint blockade resistance in cancer underlying mechanisms and current strategies to overcome resistance |
| topic | Immune checkpoint inhibitors (ICI) immune checkpoint blockade checkpoint blockade resistance immunotherapy resistance checkpoint blockade resistance mechanisms |
| url | https://www.tandfonline.com/doi/10.1080/15384047.2024.2308097 |
| work_keys_str_mv | AT ginettessantiagosanchez alandscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance AT kellsyepfabian alandscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance AT jameswhodge alandscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance AT ginettessantiagosanchez landscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance AT kellsyepfabian landscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance AT jameswhodge landscapeofcheckpointblockaderesistanceincancerunderlyingmechanismsandcurrentstrategiestoovercomeresistance |